Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Ipilimumab + Nivolumab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ipilimumab | Yervoy | BMS-734016 | CTLA4 Antibody 24 Immune Checkpoint Inhibitor 151 | Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov). |
| Nivolumab | Opdivo | MDX-1106|BMS-936558 | Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98 | Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) in patients with melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, in combination with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent NSCLC without EGFR or ALK alterations, in combination with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, in combination with Cabometyx (cabozantinib) in patients with advanced renal cell carcinoma, and in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MSH6 negative | small intestine adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | gastric adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Phase II | Actionable | In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). | 35969830 |
| PMS2 negative | gastric adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Phase II | Actionable | In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). | 35969830 |
| MSH2 negative | gastric adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Phase II | Actionable | In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). | 35969830 |
| MLH1 negative | gastroesophageal junction adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Phase II | Actionable | In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). | 35969830 |
| PMS2 negative | colon cancer | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| PMS2 negative | ampulla of Vater adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) and (ipilimumab) combination therapy is included in guidelines as first-line or subsequent therapy for metastatic ampullary adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | rectum cancer | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH2 negative | colorectal cancer | sensitive | Ipilimumab + Nivolumab | FDA approved | Actionable | In a Phase II (CheckMate 142) trial that supported FDA approval, Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment resulted in an objective response rate of 54.6% (65/119, 4 complete response, 61 partial response) and disease control over 12 weeks in 80% of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 29355075; NCT02060188). | 29355075 detail... detail... |
| PBRM1 Y106* | clear cell renal cell carcinoma | predicted - sensitive | Ipilimumab + Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment resulted in complete response in a patient with renal clear cell carcinoma harboring PBRM1 Y106* (PMID: 29301960). | 29301960 |
| MSH2 negative | small intestine adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | colon cancer | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| PBRM1 inact mut | clear cell renal cell carcinoma | sensitive | Ipilimumab + Nivolumab | Clinical Study - Cohort | Actionable | In a clinical study, renal clear cell carcinoma patients harboring PBRM1 loss-of-function mutations demonstrated improved response to immune checkpoint therapies including Opdivo (nivolumab) alone or in combination with Yervoy (ipilimumab), and Tecentriq (atezolizumab), potentially due to the distinct expression profile of immune-related genes in these patients (PMID: 29301960). | 29301960 |
| TP53 mutant | lung non-small cell carcinoma | predicted - sensitive | Ipilimumab + Nivolumab | Clinical Study - Cohort | Actionable | In a clinical study, immune checkpoint inhibitor treatment including Keytruda (pembrolizumab) (n=1), Opdivo (nivolumab) with (n=8) or without (n=63) Yervoy (ipilimumab) resulted in improved median overall survival (18.1 vs 8.1 months, HR=0.48, p=0.04), median progression-free survival (4.5 vs 1.4 months, p=0.03), and objective response rate (51.2% vs 20.7%, p=0.01) in TP53 mutant (n=41) non-small cell lung cancer patients compared to TP53 wild-type (n=31) patients (PMID: 31097096). | 31097096 |
| CD274 positive | lung non-small cell carcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Combination Opdivo (nivolumab) plus (ipilimumab) is in guidelines as first-line or subsequent therapy for advanced non-small cell lung cancer patients with CD274 (PD-L1) expression >1% and with negative status for actionable EGFR, BRAF, ALK, ROS1, RET mutations and MET exon 14 skipping mutations (NCCN.org). | detail... |
| ALK rearrange | lung non-small cell carcinoma | no benefit | Ipilimumab + Nivolumab | Guideline | Actionable | Immune checkpoint inhibitors including Keytruda (pembrolizumab), Tecentriq (atezolizumab), and the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) are not indicated for use as initial systemic therapy in non-small cell lung cancer patients harboring oncogenes, including ALK rearrangement (NCCN.org). | detail... |
| MLH1 negative | gastric adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Phase II | Actionable | In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). | 35969830 |
| MSH6 negative | gastroesophageal junction adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Phase II | Actionable | In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). | 35969830 |
| MSH2 negative | rectum cancer | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH2 negative | gastroesophageal junction adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Phase II | Actionable | In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). | 35969830 |
| MLH1 negative | ampulla of Vater adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) and (ipilimumab) combination therapy is included in guidelines as first-line or subsequent therapy for metastatic ampullary adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| PMS2 negative | rectum cancer | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| PMS2 negative | colorectal cancer | sensitive | Ipilimumab + Nivolumab | FDA approved | Actionable | In a Phase II (CheckMate 142) trial that supported FDA approval, Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment resulted in an objective response rate of 54.6% (65/119, 4 complete response, 61 partial response) and disease control over 12 weeks in 80% of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 29355075; NCT02060188). | 29355075 detail... detail... |
| CD274 positive | esophagus squamous cell carcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, TPS>=1%) (PMID: 35914638; ESMO.org). | 35914638 detail... |
| MSH6 negative | ampulla of Vater adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) and (ipilimumab) combination therapy is included in guidelines as first-line or subsequent therapy for metastatic ampullary adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | colorectal cancer | sensitive | Ipilimumab + Nivolumab | FDA approved | Actionable | In a Phase II (CheckMate 142) trial that supported FDA approval, Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment resulted in an objective response rate of 54.6% (65/119, 4 complete response, 61 partial response) and disease control over 12 weeks in 80% of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 29355075; NCT02060188). | detail... 29355075 detail... |
| MLH1 negative | rectum cancer | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as a primary therapy for advanced or metastatic rectum cancer patients with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| BRAF act mut | melanoma | predicted - sensitive | Ipilimumab + Nivolumab | Clinical Study | Actionable | In a systematic review, an analysis of several clinical trials demonstrated Opdivo (nivolumab) plus Yervoy (ipilimumab) resulted in improved overall survival (OS) compared to BRAF plus MEK inhibitor in BRAF-mutant advanced melanoma patients when considering the entire study period, and analysis of the period beginning 12 months after treatment initiation demonstrated significantly greater OS and progression-free survival (PMID: 33556898; NCT01844505, NCT01584648, NCT01597908, NCT01909453, NCT01689519). | 33556898 |
| PBRM1 K619fs | clear cell renal cell carcinoma | predicted - sensitive | Ipilimumab + Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment resulted in partial response in a patient with renal clear cell carcinoma harboring PBRM1 K619fs (PMID: 29301960). | 29301960 |
| MLH1 negative | small intestine adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH6 negative | colorectal cancer | sensitive | Ipilimumab + Nivolumab | FDA approved | Actionable | In a Phase II (CheckMate 142) trial that supported FDA approval, Opdivo (nivolumab) and Yervoy (ipilimumab) combination treatment resulted in an objective response rate of 54.6% (65/119, 4 complete response, 61 partial response) and disease control over 12 weeks in 80% of patients with microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) metastatic colorectal cancer (PMID: 29355075; NCT02060188). | detail... detail... 29355075 |
| MSH2 negative | ampulla of Vater adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) and (ipilimumab) combination therapy is included in guidelines as first-line or subsequent therapy for metastatic ampullary adenocarcinoma patients with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MLH1 negative | colon cancer | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| MSH2 negative | colon cancer | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is included in guidelines as primary or subsequent therapy for patients with advanced or metastatic colon cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| PMS2 negative | gastroesophageal junction adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Phase II | Actionable | In a Phase II trial (NEONIPIGA), neoadjuvant Opdivo (nivolumab) and Yervoy (ipilimumab) followed by surgery led to a pathological complete response in 58.6% (17/29) of patients with resectable gastric/gastroesophageal junction adenocarcinoma with high microsatellite instability or deficient mismatch repair (dMMR) (defined by loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC), and 30/31 patients in the per-protocol group were alive and progression-free at the time of analysis (PMID: 35969830; NCT0400626). | 35969830 |
| PMS2 negative | small intestine adenocarcinoma | sensitive | Ipilimumab + Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as an initial therapy for patients with advanced or metastatic small bowel adenocarcinoma with deficient mismatch repair (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03918252 | Phase II | Ipilimumab + Nivolumab Nivolumab | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | Recruiting | USA | 0 |
| NCT03126461 | Phase II | Ipilimumab + Nivolumab | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | Withdrawn | USA | 0 |
| NCT03001882 | Phase II | Ipilimumab + Nivolumab | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 2 |
| NCT02659059 | Phase II | Ipilimumab + Nivolumab | Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568) | Completed | USA | CAN | 0 |
| NCT05289193 | Phase II | Ipilimumab + Nivolumab | CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | Recruiting | USA | 0 |
| NCT03949153 | Phase Ib/II | Ipilimumab + Nivolumab | Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis (CRIRIN) | Completed | FRA | 0 |
| NCT02857569 | Phase Ib/II | Ipilimumab + Nivolumab | A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT) | Active, not recruiting | FRA | 0 |
| NCT05144529 | Phase II | Ipilimumab + Nivolumab Evolocumab + Ipilimumab + Nivolumab | A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (TOP2101) | Recruiting | USA | 0 |
| NCT03222076 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) | Completed | USA | 0 |
| NCT04300244 | Phase II | Ipilimumab + Nivolumab + UV1 Telomerase peptide vaccine Ipilimumab + Nivolumab | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU) | Active, not recruiting | ESP | 4 |
| NCT03146650 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer | Unknown status | USA | 0 |
| NCT03668119 | Phase II | Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 10 |
| NCT05176483 | Phase I | Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) | Recruiting | USA | ESP | 1 |
| NCT03430791 | Phase II | Ipilimumab + Nivolumab Nivolumab | Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | Terminated | USA | 0 |
| NCT04465643 | Phase I | Ipilimumab + Nivolumab | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor | Recruiting | USA | 0 |
| NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | ESP | DEU | CAN | 3 |
| NCT03246958 | Phase II | Ipilimumab + Nivolumab | Nivolumab Plus Ipilimumab in Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT04730544 | Phase II | Ipilimumab + Nivolumab | Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer (NIPISAFE) | Recruiting | FRA | 0 |
| NCT02869789 | Phase III | Ipilimumab + Nivolumab | A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 14 |
| NCT03061539 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature | Active, not recruiting | 1 | |
| NCT03342417 | Phase II | Ipilimumab + Nivolumab | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | Terminated | USA | 0 |
| NCT03220009 | Phase II | Ipilimumab + Nivolumab | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | Withdrawn | USA | 0 |
| NCT03903640 | Phase II | Ipilimumab + Nivolumab | Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis | Terminated | USA | 0 |
| NCT02696993 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT04966676 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS) | Recruiting | CAN | 0 |
| NCT03546686 | Phase II | Ipilimumab + Nivolumab | Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer | Recruiting | USA | 0 |
| NCT04933903 | Phase II | Ipilimumab + Nivolumab | BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | Recruiting | USA | 0 |
| NCT04090710 | Phase II | Nivolumab Ipilimumab + Nivolumab | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK) | Recruiting | CAN | 1 |
| NCT03719131 | Phase II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Rituximab | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | Recruiting | USA | 0 |
| NCT05327686 | Phase II | Axitinib + Pembrolizumab Lenvatinib + Pembrolizumab Ipilimumab + Nivolumab Avelumab + Axitinib Cabozantinib + Nivolumab | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI) | Recruiting | USA | 0 |
| NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Completed | USA | 0 |
| NCT03425292 | Phase I | Temozolomide Ipilimumab + Nivolumab Nivolumab | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer | Recruiting | USA | 0 |
| NCT05005273 | Phase II | Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | Terminated | USA | ITA | FRA | ESP | DEU | BEL | 6 |
| NCT03724968 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | Terminated | USA | 0 |
| NCT04899921 | Phase II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Trigriluzole | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | Suspended | USA | 0 |
| NCT02320058 | Phase II | Ipilimumab + Nivolumab | A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204) | Completed | USA | 0 |
| NCT03956680 | Phase I | Ipilimumab + Nivolumab BMS-986301 | An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | Active, not recruiting | USA | CAN | 0 |
| NCT04013854 | Phase II | Ipilimumab + Nivolumab Nivolumab | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | Recruiting | USA | 0 |
| NCT02599402 | Phase III | Ipilimumab + Nivolumab Nivolumab | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma | Completed | ITA | FRA | DEU | BEL | AUT | 7 |
| NCT02919683 | Phase II | Nivolumab Ipilimumab + Nivolumab | Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity | Active, not recruiting | USA | 0 |
| NCT02833233 | Phase I | Ipilimumab + Nivolumab | A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer | Active, not recruiting | USA | 0 |
| NCT02985957 | Phase II | Ipilimumab + Nivolumab | A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUT | 3 |
| NCT04026412 | Phase III | Nivolumab Ipilimumab + Nivolumab Durvalumab | A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 20 |
| NCT03149159 | Phase II | Ipilimumab + Nivolumab | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | Withdrawn | USA | 0 |
| NCT02601014 | Phase II | Ipilimumab + Nivolumab | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | Completed | USA | 0 |
| NCT03355976 | Phase II | Ipilimumab + Nivolumab Nivolumab | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | Recruiting | USA | 0 |
| NCT04323046 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | Active, not recruiting | USA | 3 |
| NCT02714218 | Phase III | Ipilimumab + Nivolumab | A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma | Completed | USA | ITA | FRA | ESP | DEU | CAN | 7 |
| NCT04340193 | Phase III | Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 13 |
| NCT03235245 | Phase II | Binimetinib + Encorafenib Ipilimumab + Nivolumab | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) | Recruiting | ITA | FRA | ESP | DEU | BEL | 3 |
| NCT04311710 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) | Active, not recruiting | USA | ITA | 1 |
| NCT03604991 | Phase II | Carboplatin + Paclitaxel Nivolumab Carboplatin + Nivolumab + Paclitaxel Ipilimumab + Nivolumab | Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma | Suspended | USA | 0 |
| NCT03420521 | Phase II | Ipilimumab + Nivolumab | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | Terminated | USA | 0 |
| NCT03528408 | Phase II | Ipilimumab + Nivolumab | Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma | Active, not recruiting | USA | 0 |
| NCT03233152 | Phase I | Ipilimumab + Nivolumab | Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma (GlitIpNi) | Recruiting | BEL | 0 |
| NCT03776487 | Phase Ib/II | Fluorouracil + Oxaliplatin Nivolumab Ipilimumab + Nivolumab Fluorouracil + Ipilimumab + Nivolumab | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | Recruiting | USA | 0 |
| NCT04511013 | Phase II | Ipilimumab + Nivolumab Binimetinib + Encorafenib + Nivolumab | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | Recruiting | USA | 0 |
| NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Recruiting | CAN | 0 |
| NCT03215706 | Phase III | Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 12 |
| NCT04575922 | Phase II | Ipilimumab + Nivolumab | Nivolumab+Ipilimumab+RT in MSS mCRC | Active, not recruiting | USA | 0 |
| NCT03367715 | Phase II | Ipilimumab + Nivolumab | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | Completed | USA | 0 |
| NCT03307616 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma | Active, not recruiting | USA | 0 |
| NCT04361162 | Phase II | Ipilimumab + Nivolumab | Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer | Active, not recruiting | USA | 0 |
| NCT03256136 | Phase II | Carboplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab | A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer | Completed | USA | 0 |
| NCT03083691 | Phase II | Ipilimumab + Nivolumab | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | Enrolling by invitation | DEU | 0 |
| NCT03138512 | Phase III | Ipilimumab + Nivolumab | A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 17 |
| NCT04118166 | Phase II | Ipilimumab + Nivolumab | Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
| NCT02996110 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC) | Completed | USA | ITA | CAN | AUT | 2 |
| NCT04967196 | Phase I | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma | Recruiting | USA | 0 |
| NCT05361720 | Phase II | Cabozantinib + Nivolumab Ipilimumab + Nivolumab | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | Recruiting | USA | 0 |
| NCT02899299 | Phase III | Carboplatin + Cisplatin + Pemetrexed Disodium Ipilimumab + Nivolumab | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743) | Active, not recruiting | USA | ITA | FRA | DEU | BEL | 16 |
| NCT02017717 | Phase III | Nivolumab Bevacizumab Ipilimumab + Nivolumab | A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 6 |
| NCT03029780 | Phase II | Ipilimumab + Nivolumab | An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma | Completed | USA | 2 |
| NCT05341349 | Phase I | Ipilimumab + Nivolumab Pembrolizumab | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases | Recruiting | USA | 0 |
| NCT02823574 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | ITA | FRA | ESP | CAN | BEL | 15 |
| NCT02970981 | Phase II | Ipilimumab + Nivolumab | Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma | Completed | USA | 0 |
| NCT02231749 | Phase III | Ipilimumab + Nivolumab Sunitinib | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 20 |
| NCT04741438 | Phase III | Ipilimumab + Nivolumab Pazopanib | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) | Recruiting | FRA | 0 |
| NCT03707457 | Phase I | Ipilimumab + Nivolumab MK-4166 + Nivolumab Epacadostat + Nivolumab | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | Terminated | USA | 0 |
| NCT03305445 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL | Completed | USA | 0 |
| NCT03575793 | Phase Ib/II | Ipilimumab + Nivolumab + Plinabulin Ipilimumab + Nivolumab | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT02186249 | Phase III | Ipilimumab + Nivolumab | Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218) | No longer available | USA | CAN | 0 |
| NCT03793166 | Phase III | Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab | Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer | Recruiting | USA | 1 |
| NCT02785952 | Phase III | Nivolumab Ipilimumab + Nivolumab | Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | Active, not recruiting | USA | CAN | 0 |
| NCT05077280 | Phase II | Ipilimumab + Nivolumab | A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma | Recruiting | USA | 0 |
| NCT03406247 | Phase II | Ipilimumab + Nivolumab Nivolumab | Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (ADJORL1) | Recruiting | FRA | 0 |
| NCT05310643 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy (NIPIRESCUE) | Recruiting | FRA | 0 |
| NCT02659540 | Phase I | Ipilimumab + Nivolumab | A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma | Completed | USA | 0 |
| NCT05041062 | Phase II | Ipilimumab + Nivolumab | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | Recruiting | USA | 0 |
| NCT03333616 | Phase II | Ipilimumab + Nivolumab | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | Recruiting | USA | 0 |
| NCT03463408 | Phase I | Ipilimumab + Nivolumab | Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
| NCT05169957 | Phase I | Ipilimumab + Nivolumab | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | Recruiting | USA | 0 |
| NCT05012254 | Phase II | Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium | Study of Nivolumab and Ipilimumab Plus Chemotherapy as a Treatment for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain) | Recruiting | ESP | 0 |
| NCT03597282 | Phase I | Ipilimumab + Nivolumab APX005M + Nivolumab Ipilimumab + NEO-PV-01 + Nivolumab + Poly ICLC APX005M + NEO-PV-01 + Nivolumab + Poly ICLC Nivolumab + Poly ICLC NEO-PV-01 + Nivolumab + Poly ICLC | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | Terminated | USA | 0 |
| NCT04013542 | Phase I | Ipilimumab + Nivolumab Nivolumab | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer | Recruiting | USA | 0 |
| NCT04256213 | Phase 0 | Ipilimumab + Nivolumab | COL Immunotherapy Before Radiochimio + Ipilimumab (COLIBRI) | Active, not recruiting | FRA | 0 |
| NCT04145115 | Phase II | Ipilimumab + Nivolumab | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden | Recruiting | USA | 1 |
| NCT03799445 | Phase II | Ipilimumab + Nivolumab | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | Recruiting | USA | 0 |
| NCT05148546 | Phase II | Ipilimumab + Nivolumab Nivolumab Nivolumab + Relatlimab | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer (NESCIO) | Recruiting | 2 | |
| NCT05112601 | Phase II | Ipilimumab + Nivolumab Nivolumab | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | Recruiting | USA | 0 |
| NCT03425331 | Phase II | Ipilimumab + Nivolumab | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | Suspended | USA | 0 |
| NCT02978443 | Phase II | Ipilimumab + Nivolumab | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | Unknown status | USA | 0 |
| NCT05219435 | Phase II | Ipilimumab + Nivolumab | Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (VEXILLUM) | Recruiting | ESP | 0 |
| NCT02304458 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Active, not recruiting | USA | CAN | 0 |
| NCT03203473 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) | Active, not recruiting | USA | 0 |
| NCT04039607 | Phase III | Lenvatinib Sorafenib Ipilimumab + Nivolumab | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 18 |
| NCT04495010 | Phase II | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA) | Withdrawn | USA | ITA | FRA | ESP | DEU | BEL | AUT | 9 |
| NCT04429321 | Phase I | Ipilimumab + Nivolumab | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary | Recruiting | USA | 0 |
| NCT03274258 | Phase II | Ipilimumab + Nivolumab | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | Active, not recruiting | USA | 0 |
| NCT05199285 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Liver Cancer | Recruiting | USA | 0 |
| NCT04382664 | Phase II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Sargramostim + UV1 Telomerase peptide vaccine | UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | Recruiting | USA | BEL | 2 |
| NCT04042753 | Phase II | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors | Recruiting | USA | 0 |
| NCT02408861 | Phase I | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors | Recruiting | USA | 1 |
| NCT03391869 | Phase III | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
| NCT04008030 | Phase III | Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 16 |
| NCT03437200 | Phase II | Nivolumab Ipilimumab + Nivolumab | Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer (CRUCIAL) | Unknown status | FRA | ESP | 0 |
| NCT04823403 | Phase I | Ipilimumab + Nivolumab | Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma (HIPANIV) | Recruiting | FRA | 0 |
| NCT04080804 | Phase II | Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | Recruiting | USA | 0 |
| NCT05153304 | Phase Ib/II | Ipilimumab + Nivolumab | A Phase I/II Study of Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers | Not yet recruiting | USA | 0 |
| NCT03172624 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | Active, not recruiting | USA | 0 |
| NCT01940809 | Phase II | Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
| NCT03033576 | Phase II | Ipilimumab Ipilimumab + Nivolumab | Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
| NCT04088500 | Phase II | Ipilimumab + Nivolumab | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma | Terminated | USA | CAN | 0 |
| NCT02892734 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | Terminated | USA | 0 |
| NCT03158129 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection | Active, not recruiting | USA | 0 |
| NCT04250246 | Phase II | Ipilimumab + Nivolumab Guadecitabine + Ipilimumab + Nivolumab | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1) | Not yet recruiting | ITA | 0 |
| NCT02741570 | Phase III | Carboplatin + Cetuximab + Cisplatin + Fluorouracil Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | ITA | FRA | ESP | DEU | AUT | 12 |
| NCT03749460 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | Active, not recruiting | USA | 0 |
| NCT03693846 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Terminated | USA | 0 |
| NCT03651271 | Phase II | Ipilimumab + Nivolumab Nivolumab | Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer | Active, not recruiting | USA | 0 |
| NCT03101566 | Phase II | Cisplatin + Gemcitabine + Nivolumab Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer | Completed | USA | 0 |
| NCT02681302 | Phase Ib/II | Ipilimumab + Nivolumab | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001) | Active, not recruiting | USA | 0 |
| NCT02939300 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma | Completed | USA | 0 |
| NCT03203304 | Phase I | Nivolumab Ipilimumab + Nivolumab | Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma | Terminated | USA | 0 |
| NCT03104439 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | Recruiting | USA | 0 |
| NCT04326257 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy | Recruiting | USA | 0 |
| NCT03670056 | Phase II | Ipilimumab + Nivolumab | A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy | Active, not recruiting | USA | 0 |
| NCT03377023 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nintedanib + Nivolumab | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT03873402 | Phase III | Nivolumab Ipilimumab + Nivolumab | An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | Active, not recruiting | USA | ITA | FRA | ESP | AUT | 9 |
| NCT03036098 | Phase III | Cisplatin + Gemcitabine Ipilimumab + Nivolumab Carboplatin + Gemcitabine | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 25 |
| NCT03798639 | Phase I | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | Active, not recruiting | USA | 0 |
| NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
| NCT02224781 | Phase III | Ipilimumab + Nivolumab Dabrafenib + Trametinib | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | Active, not recruiting | USA | 0 |
| NCT03508570 | Phase I | Nivolumab Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | Active, not recruiting | USA | 0 |
| NCT03646617 | Phase II | Ipilimumab + Nivolumab | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | Recruiting | USA | 0 |
| NCT03043599 | Phase Ib/II | Ipilimumab + Nivolumab | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT03065179 | Phase II | Ipilimumab + Nivolumab | Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients | Completed | USA | 0 |
| NCT03682276 | Phase Ib/II | Ipilimumab + Nivolumab | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma (PRIME-HCC) | Recruiting | 1 | |
| NCT03937219 | Phase III | Cabozantinib + Nivolumab Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 17 |
| NCT02210117 | Phase II | Nivolumab Bevacizumab + Nivolumab Ipilimumab + Nivolumab | Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC) | Unknown status | USA | 0 |
| NCT02880020 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
| NCT04949113 | Phase III | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA) | Recruiting | USA | 2 |
| NCT03591731 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC) | Active, not recruiting | FRA | 0 |
| NCT02846376 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | Active, not recruiting | USA | 0 |
| NCT04606316 | Phase I | Nivolumab Ipilimumab + Nivolumab | Surgical Nivolumab And Ipilimumab For Recurrent GBM | Recruiting | USA | 0 |
| NCT02350764 | Phase II | Ipilimumab + Nivolumab | Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs | Active, not recruiting | USA | 0 |
| NCT03340129 | Phase II | Ipilimumab + Nivolumab | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X) | Recruiting | 2 | |
| NCT03068455 | Phase III | Nivolumab Ipilimumab Ipilimumab + Nivolumab | A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 11 |
| NCT03789110 | Phase II | Ipilimumab + Nivolumab | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03829111 | Phase I | Ipilimumab + Nivolumab CBM588 + Ipilimumab + Nivolumab | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | Active, not recruiting | USA | 0 |
| NCT03520491 | Phase II | Ipilimumab + Nivolumab Nivolumab | A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | Recruiting | USA | 0 |
| NCT03048136 | Phase III | Ipilimumab + Nivolumab | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955) | Withdrawn | USA | DEU | CAN | 2 |
| NCT03285321 | Phase II | Ipilimumab + Nivolumab Nivolumab | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | 0 |
| NCT02982954 | Phase III | Ipilimumab + Nivolumab | A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920) | Completed | USA | 0 |
| NCT03600155 | Phase I | Nivolumab Ipilimumab Ipilimumab + Nivolumab | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia | Recruiting | USA | 0 |
| NCT03162731 | Phase I | Ipilimumab + Nivolumab | Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer | Completed | USA | 0 |
| NCT03818685 | Phase II | Ipilimumab + Nivolumab Capecitabine | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03) | Active, not recruiting | FRA | 0 |
| NCT02656706 | Phase II | Ipilimumab + Nivolumab | BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial | Active, not recruiting | USA | 0 |
| NCT03071406 | Phase II | Ipilimumab + Nivolumab | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT02935634 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC) | Active, not recruiting | USA | ITA | DEU | CAN | 5 |
| NCT03604978 | Phase Ib/II | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Participants With Recurrent Grade II-III Meningioma | Recruiting | USA | 0 |
| NCT04006262 | Phase II | Ipilimumab + Nivolumab | Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma (NEONIPIGA) | Recruiting | FRA | 0 |
| NCT03241186 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | Active, not recruiting | USA | 0 |
| NCT04007588 | Phase II | Ipilimumab + Nivolumab Nivolumab BMS-986205 + Nivolumab | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | Withdrawn | USA | 0 |
| NCT03130959 | Phase II | Ipilimumab + Nivolumab Nivolumab | An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) | Completed | USA | FRA | ESP | DEU | CAN | 10 |
| NCT03521830 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | Recruiting | USA | 0 |
| NCT04131621 | Phase II | Nivolumab Ipilimumab Ipilimumab + Nivolumab | Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP) | Unknown status | DEU | 0 |
| NCT04416568 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | Recruiting | USA | 0 |
| NCT03335540 | Phase I | BMS-986205 + Nivolumab Nivolumab + Relatlimab Cabiralizumab + Nivolumab Lirilumab + Nivolumab BMS-986156 + Nivolumab Ipilimumab + Nivolumab Nivolumab | An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | Completed | USA | 0 |
| NCT02998528 | Phase III | Ipilimumab + Nivolumab Carboplatin + Cisplatin + Docetaxel + Gemcitabine + Pemetrexed Disodium + Vinorelbine | A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | 10 |
| NCT02864251 | Phase III | Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Pemetrexed Disodium | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722) | Completed | USA | FRA | ESP | CAN | 6 |
| NCT04938232 | Phase II | Ipilimumab + Nivolumab | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | Recruiting | USA | 0 |
| NCT03262779 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. | Completed | USA | 0 |
| NCT04500548 | Phase I | Nivolumab Ipilimumab + Nivolumab | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | Withdrawn | USA | CAN | 0 |
| NCT04396860 | Phase II | Temozolomide Ipilimumab + Nivolumab | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | Suspended | USA | 0 |
| NCT02872116 | Phase III | Capecitabine + Oxaliplatin Ipilimumab + Nivolumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 23 |
| NCT03570619 | Phase II | Ipilimumab + Nivolumab | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT) | Active, not recruiting | USA | 0 |
| NCT02154490 | Phase II | Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
| NCT03461952 | Phase II | Nivolumab Ipilimumab + Nivolumab | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) | Active, not recruiting | USA | CAN | 0 |
| NCT03143153 | Phase III | Ipilimumab + Nivolumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Nivolumab | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | AUT | 21 |
| NCT05116202 | Phase Ib/II | RO7247669 Atezolizumab + Tiragolumab Ipilimumab + Nivolumab RO7247669 + Tiragolumab | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | Recruiting | USA | ITA | FRA | ESP | 2 |
| NCT03223155 | Phase I | Ipilimumab + Nivolumab | Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
| NCT03443856 | Phase II | Ipilimumab + Nivolumab | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence (VESTIGE) | Active, not recruiting | ITA | FRA | ESP | DEU | 5 |
| NCT02736123 | Phase Ib/II | Nivolumab Ipilimumab + Nivolumab | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | Withdrawn | USA | 0 |
| NCT03075423 | Phase II | Sunitinib Ipilimumab + Nivolumab | Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (SUNIFORECAST) | Active, not recruiting | FRA | ESP | DEU | BEL | 3 |
| NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Recruiting | USA | 1 |
| NCT05004025 | Phase I | Ipilimumab + Nivolumab | Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | Recruiting | USA | 0 |
| NCT03122522 | Phase II | Nivolumab Ipilimumab + Nivolumab | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | Active, not recruiting | USA | 0 |
| NCT04969887 | Phase II | Ipilimumab + Nivolumab | Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) | Recruiting | 1 | |
| NCT04751370 | Phase II | Ipilimumab + Nivolumab | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer | Recruiting | USA | 0 |
| NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
| NCT03823625 | Phase II | Ipilimumab + Nivolumab Carboplatin + Gemcitabine + Nivolumab Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (SQUINT) | Unknown status | ITA | 0 |
| NCT03117309 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT03469960 | Phase III | Ipilimumab + Nivolumab | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE) | Active, not recruiting | FRA | 0 |
| NCT04462406 | Phase II | Pembrolizumab Nivolumab + Pembrolizumab Ipilimumab + Nivolumab Ipilimumab + Pembrolizumab Nivolumab | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | Recruiting | USA | 0 |
| NCT05302921 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | Recruiting | USA | 0 |
CKB BOOST